PEPTONIC Medical is commercializing VagiVital™ – a hormone free treatment for vaginal atrophy (VA). The product is a vaginal gel for topical administration.
PEPTONIC Medical is commercializing VagiVital™ – a hormone free treatment for vaginal atrophy (VA). The product is a vaginal gel for topical administration.
Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.
VagiVital™ has been studied in randomized, double-blind and placebo controlled clinical trials. The product has shown positive effects on both objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective signs (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) of vaginal atrophy. It was very well tolerated and caused no serious adverse effects.
The pipeline of PEPTONIC Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
In July 2014, PEPTONIC Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.